Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7549 USD -3.22% Market Closed
Market Cap: 26.7m USD

Equillium Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Equillium Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Equillium Inc
NASDAQ:EQ
Capital Expenditures
-$111k
CAGR 3-Years
-7%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$974m
CAGR 3-Years
-7%
CAGR 5-Years
-12%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$523m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
1%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$1.1B
CAGR 3-Years
-8%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$485.4m
CAGR 3-Years
-27%
CAGR 5-Years
-45%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$881.6m
CAGR 3-Years
-17%
CAGR 5-Years
-15%
CAGR 10-Years
-10%

Equillium Inc
Glance View

Market Cap
26.7m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
0.847 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Equillium Inc's Capital Expenditures?
Capital Expenditures
-111k USD

Based on the financial report for Sep 30, 2024, Equillium Inc's Capital Expenditures amounts to -111k USD.

What is Equillium Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-13%

Over the last year, the Capital Expenditures growth was -455%. The average annual Capital Expenditures growth rates for Equillium Inc have been -7% over the past three years , -13% over the past five years .

Back to Top